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E-mail address: latif@birzeit.eduThe complexes ce:italic>/ce:italic>-bis (1,2-dimethylimidazole) bis (salicylato) copper (II) (1) and tris (2-
methylimidazole) (salicylato) copper (II) (2) have been prepared by the reaction of appropriate methyl-
imidazole derivative with binuclear copper (II) aspirinate. Spectral and X-ray structural studies for com-
plex 1 showed that the copper ion is coordinated in a ce:italic>/ce:italic> arrangement to two imidazole
nitrogen atoms and two carboxylate oxygen atoms from the salicylate mono-anion ligands. The second
carboxylate oxygen atoms form weak axial interactions with the copper ion. Spectral, magnetic and ana-
lytical data for complex 2 showed that the copper ion is bonded to three 2-methylimidazole nitrogen
atoms and one doubly deprotonated salicylate di-anion, which is chelated to Cu (II) ion through one of
its carboxylate oxygen atoms and the deprotonated hydroxyl oxygen atom to form distorted square-pyra-
midal geometry having CuN3O + O chromophore. The superoxide dismutase (SOD) mimetic activities
(IC50) of the complexes1, 2 and the structurally knownmixture complexes Cu (imidazole)n(salicylato)2(3)
(where n = 2, 5 and 6) were determined using the xanthine–xanthine oxidase assay and compared with
those reported for other copper (II) complexes with anti-inﬂammatory drugs. The results obtained indi-
cated that complexes 1–3 have high SOD-like activities, which may act as good mimics for native Cu, Zn–
SOD enzyme.
 2010 Elsevier B.V. All rights reserved.1. Introduction
Many copper (II) complexes of pharmacologically active ligands
have been shown to be more effective in treatment diseases than
the parent ligands [1,2]. Salicylic acid (a) and its derivatives have
been used for many years as anti-inﬂammatory, antipyretic and
analgesic drugs. Binary and ternary Cu (II) complexes of salicylic
acid and its derivatives with basic ligands have been found to ex-
hibit several pharmacological effects suggesting treatment of many
pathological disease states [3–10]. These disease states include
many inﬂammations, seizures, gastric and intestinal ulcers,
diabetes, neoplasias carcinogenesis, convulsion, mutagenesis,
ischemia–reperfusion injury, and radiation injury. All of these
pharmacological effects of Cu (II) salicylate type complexes have
been attributed to their anti-oxidative activities against the reac-
tive oxygen species, especially superoxide radical anion (O2 ),
which are the cause of these diseases.
Reactive superoxide which is produced through metabolic reac-
tions resulting from aerobic respiration is controlled by one of thell rights reserved.enzymes Cu, Zn-superoxide dismutase (SOD) [11]. In this enzyme
the copper (II) ion is the active center and coordinated to four imid-
azole nitrogen atoms from histidine residues in which one imidaz-
ole is bridging ligand between Cu (II) and Zn (II) ions. In addition, a
water molecule is coordinated to copper ion at the axial position of
a distorted square pyramidal conﬁguration. The main function of
the Zn (II) ion is to stabilize the enzyme structure and can be re-
placed by another atom or removed without any signiﬁcant effect
on the activity of the enzyme [11b]. The use of SOD enzyme as
pharmaceutical agent is limited because of its instability and low
membrane permeability, resulting from its high molecular weight
(about 32 KDa). So, low molecular weight mononuclear and binu-
clear Cu (II) complexes have designed and synthesized as mimics
for Cu, Zn–SOD [5–7,12–33], including binary and ternary copper
complexes of anti-inﬂammatory drugs [2,5–7,2–22]. Because the
native SOD enzyme has four imidazole nitrogen atoms coordinated
to Cu (II) [11], it was proposed that the presence of coordination
sites belonging to nitrogen hetero-aromatic rings such as imidaz-
ole, pyridine and pyrazole is important for high SOD activity
[15,29,30]. Therefore, we selected imidazole and its methyl deriv-
atives as auxiliary ligands to prepare ternary copper (II) salicylate
complexes. Recently, we reported the characterization of mononu-
clear copper (II) salicylate imidazole and N-methylimidzole com-
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mononuclear geometries in a unit cell: the ce:italic>/ce:italic>bis,
pentakis- and hexakis-imidazole complexes of copper (II) salicylate
[34]. The N-methylimdazole has formed a mononuclear hexakis –
adduct of copper (II) salicylate, and was found to be active SOD mi-
mic [20]. To study the inﬂuence of substituent of the imidazole ring
in the coordination polyhedron of copper (II) ion which might have
inﬂuence on the superoxide activity of copper (II) salicylate ad-
ducts, we have studied the interaction of 1,2-dimethylimidazole
(b) and 2-methylimidazole (c) with copper (II) salicylate. Herein,
we report the synthesis, spectral characterization of the ternary
copper (II) salicylate complexes with 1,2-dimethylimidazole and
2-methylimidazole (Scheme 1), as well the X-ray molecular struc-
ture of 1,2-dimethylimidazole adduct. Because the pharmacologi-
cal effects, mentioned above, of Cu (II) salicylate type complexes
are attributed to their superoxide dismutase (SOD) activity and to
throw some light on the structure–SOD activity relationship of
this simple class and low molecular weight of complexes, we
studied the SOD like activity of these new complexes and of the
copper (II) salicylate imidazole mixture adducts [34] and com-















































Scheme 1. Syntheses of(N-methylimidazole) copper (II) salicylate adduct [20]. In addi-
tion, the activities of the complexes are also compared to the
activities of native Cu, Zn–SOD and other mononuclear and binu-



















































complexes 1 and 2.
Table 1
Crystal data for complex 1.











d (calcd) (g/cm3) 1.451
Radiation, k (Å) Mo; 0.71073
Temp. (C) 100




a R = R||Fo|  |Fc||/R|Fo|.
b Rw = [Rw(|Fo|  |Fc|)2/Rw|Fo|2]1/2.2.1. Reagents and materials
All chemicals were of high purity grade (Aldrich or Sigma
chemicals) and were used without further puriﬁcations. Tetrakis-
l-aspirinato dicopper (II) [Cu2(asp)4] was prepared as described
previously [35]. The three copper geometries mixture of mononu-
clear complexes of the type Cu(imidazole)n(salicylate)2(3) (where
n = 2, 5 and 6) was previously prepared in our laboratory [34].
2.2. Preparation of complexes
2.2.1. Preparation of bis(1,2-dimethylimidazole) bis(salicylato) copper
(II)
[Cu(1,2-MeIm)2(Hsal)2](1). A solution of excess 1,2-dimethyl-
imidazole (4 mL = 45 mmol) in 15 mL of methanol was added to
0.5 g (0.59 mmol) of copper(II) aspirinate [Cu2(asp)4], and the blu-
ish-green solution was stirred at 50–60 C for 3 h, ﬁltered and left
in the hood to evaporate. Re-crystallization of the bluish-green
precipitate from hot CH2Cl2 produced green crystal. Anal. Calc:
for C24H26N4O6Cu: C, 54.39; H, 4.91; N, 10.58%. Found: C, 54.31;
H, 4.85; N, 10.43%.
2.2.2. Preparation of tris(2-methylimidozole) (salicylato) copper (II)
[Cu(2-MeIm)3(sal)](2). An excess of 2-methylimidazole (1 g =
12 mmol) in a 10 mL of chloroform was added to 0.5 g (0.59 mmol)
of copper (II) aspirinate [Cu2(asp)4]. The mixture was stirred in an
ice bath for 10 h. Anhydrous diethyl ether was added to the mix-
ture and stirring was continued at room temperature until a green
precipitate formed. The solution was ﬁltered under reduced pres-
sure and the green precipitate was washed several times with
chloroform and anhydrous diethyl ether and air dried. Attempts
to grow crystals suitable for X-ray analysis were unsuccessful. Anal.
Calc: for C19H22N6O3Cu: C, 51.18; H, 4.94; N, 18.85%. Found: C,
51.04; H, 5.02; N, 18.63%.
The syntheses of these complexes are summarized and pre-
sented in Scheme 1 as shown below.
2.3. Physical measurements
Room temperature (298 K) magnetic susceptibility measure-
ments of powdered samples were determined by the Gouymethod,
with HgCo(NCS)4 as calibrant, and corrected for diamagnetismwith
the appropriate Pascal constant. The effective magnetic moment
was calculated from the expression:leff = 2.84 (vM  T)1/2. Electronic
spectra of methanol solutions were obtained on Hewlett Packard
8425A diode array spectrophotometer. Nujol mulls sealed between
polyethylene sheets were used to obtained IR spectra of the com-
plexes in the 4000–450 cm1 region with an FTS-7 Bio-Rad SPC
3200 Fourier transform infrared spectrometer. The ESR spectra of
powered and methanol/toluene solutions were taken at different
temperatureswith aVarianE-4X-band spectrometer equippedwith
a variable temperature unit and 100 kHz ﬁeld modulation. Diph-
enylpicrylhydrazide (DPPH, g = 2.0036) was used as the calibrating
ﬁeld marker. Elemental analysis for C, H and N were performed by
Galbraith Laboratories, Knoxville, TN, USA.
2.4. X-ray structure determination
The method for obtaining and acquisition of crystallographic
data was as described previously [34]. A summary of these data
is given in Table 1. Green crystals of complex 1 were grown from
hot CH2Cl2. Data were collected over the 2h range of 3.5–45
(0 6 h 6 12, 0 6 k 6 26, 11 6 l 6 11). The unit cell parameters
were obtained from the least squares ﬁt of 20 reﬂections. Of the1600 unique reﬂections measured, 1292 with Fo > 4.0r(Fo) were
used during full-matrix least squares reﬁnement. The weighting
scheme used was w1 = r2(F) + 0.0005F2. The largest peak in the ﬁ-
nal difference map was 0.32 e Å3.
2.5. Superoxide dismutase assay
Superoxide dismutase activity was assayed, as described previ-
ously [16,20], using the xanthine–xanthine oxidase system for the
production of superoxide and iodophenyl-nitrophenyl–phenylt-
razolium salt (INT) reduction at 510 nm for the superoxide detec-
tion. The reaction mixture contained 8.5  105 M xanthine and
1.5  104 M INT in 0.05 M phosphate buffer solution at pH 7.8.
The reaction was started by the addition of xanthine oxidase in
the amount needed to yield an absorbance change of 0.03–0.04
units per minute at 510 nm in the absence of the copper complex.
The SOD mimetic activity of the copper complex at 25 C was eval-
uated from the absorbance decrease at 510 nm comparing to the
blank (the reaction mixture without the copper complex). A unit
SOD activity is the concentration of the complex or enzyme which
causes 50% inhibition reduction of INT (the IC50 value). The IC50 va-
lue for each complex was obtained from the plot of percentage of
inhibition versus the complex concentration.
3. Results and discussion
3.1. Spectroscopic and magnetic characterization
Complexes 1 and 2 are the product of the slow reaction of binu-
clear copper (II) aspirinate [Cu2(asp)4], with methylimidazole
derivatives (scheme 1). During the reaction and/or re-crystalliza-
tion the acetoxy group of the aspirinate ligand undergoes hydroly-
sis to give the salicylate ligand. The stretching frequency of the
acetoxy carbonyl moiety of the aspirinate ligand occurs near
1750 cm1 for mononuclear copper (II) aspirinate complexes and
at 1758 and 1725 cm1 for the binuclear copper (II) aspirinate
[36]. The complexes do not exhibit the C@O stretching frequency
in this region, suggesting that the acetoxy group has been lost. This
is conﬁrmed by the solid state structure for complex 1 (vide infra).
The antisymmetric masy(COO) and symmetric msy(COO) carboxylate
stretching vibrations for the coordinated mono-anion salicylate
(Hsal1) in 1 appear as doublets occurring at 1601 and 1585 cm1
and at 1414 and 1392 cm1, respectively. For complex 2 the masy(COO)
and msy(COO) frequencies for the coordinateddi-anion salicylate(sal2)
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boxylate stretching vibrations and the separation between masy(COO)
andmsy(COO),Dm, of187–193 cm1 in1andof193 cm1 in2, arewithin
the range expected for carboxylate groups that act as ‘‘unsymmetrical”
bidentate or as monodentate coordination ligand [34,37]. This coordi-
nationmode in complex 1 is borne out by the solid-state structure (see
below). The m(C–C) stretching vibrations of the salicylate aromatic ring
occur at 1613 and 1556 cm1 in complex 1 and at 1562 cm1 in com-
plex 2. The m(C–O) of the phenolic group occurs at 1254 in 1 and 2
and the bending frequency of the phenyl ring–O–H, d(Ph–O–H),occurs
at 1344 cm1 in complex 1, but this frequency is absent in complex 2
which indicates coordination of phenolic oxygen to copper atom
[38,39]. This coordination also may explain the change in the m(C–C)
ring vibrations in 2, compare to those for 1, due to change in the Ph–
Obondorder andchange in chargedensitydistributionon thebenzene
ring [39].
The d–d transitions for 1 and 2 in methanol solutions occur at
690 nm (M = 85) and 656 nm (M = 75), respectively. A band be-
tween 400 and 450 nm previously reported for mononuclear cop-
per (II) salicylate compounds was ascribed to a ligand-to-metal
charge transfer transition [34,40]. The spectra of complexes 1
and 2 exhibit shoulders at ca. 400 nm. The kmax of the d–d transi-
tion of 1 at 690 nm is in the range expected for mononuclear cop-
per (II) complexes that contain the chromophore CuN2O2  O2
[36,41,42] and thus is consistent with the formation of [Cu(1,2-
MeIm)2(Hsal)2] complex which has the CuN2O2  O2 chromophore.
The kmax for the d–d transition in complex 2 occurs at higher en-
ergy than that of complex 1, which indicates a stronger ligand ﬁeld
in the Cu (II) plane. A survey of the electronic data of copper (II)
complexes that contain nitrogen and oxygen donor atoms inFig. 1. X-band ESR spectrum of [Cu(2-MeIm)3(sal)](2) as: (A) powsquare planar or tetragonally distorted octahedral geometry, stud-
ied in the same solvent, indicated that as the number of nitrogen
donors increases the energy of the d–d transition increases. This
is attributed to stronger ligand ﬁeld for nitrogen donor ligands
compare to oxygen donor ligands. Spectroscopic results as well
as X-ray structural determination (see below) indicated that com-
plex 1 has two imidazole nitrogen atoms and two carboxylate oxy-
gen atoms in the copper (II) plane. The electronic results indicated
that there are more than two nitrogen atoms in the plane of Cu (II)
in complex 2. And since electronic spectra for complexes which
have four imidazole nitrogen atoms in the Cu (II) plane, such as
hexakis (N-methylimidazole) copper (II) bis (salicylate) [20], and
tetrakis (imidazole or N-methylimidazole) bis (aspirinato) copper
(II) complexes [36] exhibit kmax at about 630 nm in methanol solu-
tions, complex 2 is expected to have three imidazole nitrogen
atoms in the Cu (II) plane showing kmax at 656 nm. These electronic
results for complex 2 are supported by electron spin resonance
(ESR) spectroscopy studies of this complex as discussed below.
The room temperature X-band ESR spectrum of a polycrystalline
sample of complex 2 is shown in Fig. 1A. The spectrum is clearly that
of a rhombic systemwithg1 = 2.194,g2 = 2.081, andg3 = 2.032. These
results suggest that there is a pronounced distortion form square
planar symmetry. Such spectra are characteristic of a distorted trigo-
nal–bipyramidal or a distorted square–pyramidal geometry [43].
ThepolycrystallineESRspectrumis slightly temperature-dependent
with g1 = 2.192, g2 = 2.066, g3 = 2.035 at 196 C. The spectrum is
consistent with a copper (II) complex that has a distorted-square
base arrangement. The room-temperature ESR spectrum of 2 in
methanol is isotropic and consists of the four equally-spaced lines
expected for hyperﬁne coupling of the unpaired electron with theder at room temperature and (B) frozen solution at –196 C.
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Ao = 66  104 cm1. The frozen-solution spectrum, Fig. 1B, is that
of an axial system with g|| = 2.254, gx = 2.061, gy = 2.013, and A|| =
177  104 cm1, suggesting a dx2–y2 (or dxy) ground state that is
characteristic of square symmetry [43,44]. In addition to the hyper-
ﬁne structure of copper (II) in the g|| region, the gxy signals and the
lowest-ﬁeld component of the g|| signal exhibit 14N super-hyperﬁne
structure that consists of seven lines with Axy (N) = 14  104 cm1
and A|| (N) = 11.5  104 cm1. The seven-line pattern is attributed
to the interaction of the unpaired electronwith three 2-methylimid-
azole nitrogen donor atoms in the plane of the copper (II) ion.
The room temperature (298 K) solid-state magnetic moments
for the two adducts are 1.88 and 1.85 BM for complexes 1 and 2,
respectively. These values are consistent with the presence of
one unpaired electron in a mononuclear copper (II) complexes.
Collectively these spectral and magnetic results along with ana-
lytical data indicate that Cu (II) ion in complex 2 is coordinated to
three 2-methylimidazole ligands and one doubly deprotonated
salicylate ion (sal2), which is chelated to Cu (II) ion through one
of its carboxylate oxygen atoms and the deprotonated hydroxyl
oxygen atom to form Cu(2-MeIm)3(sal) complex which has dis-
torted square pyramidal CuN3O + O chromophore (Scheme 1).3.2. X-ray crystal structure of complex 1
The structure of complex 1 with the atomic labeling is illus-
trated in Fig. 2. The complex crystallizes with four close donor
atoms in a distorted cis-square plane and two weakly coordinating
atoms above and below the plane. The four closest donor atoms
consist of two nitrogen atoms from the two 1,2-dimethylimid-
azole ligands with Cu–N distances of 1.979 Å and two carboxylate
oxygen atoms from the two salicylate ions with Cu–O distances of
1.981 Å. The remaining two carboxylate oxygen atoms are weakly
coordinated to Cu (II) in the axial positions with Cu–O distances of
2.590 Å. The bond distances in 1 are comparable with the analo-
gous distances in other mononuclear copper (II) carboxylates with
1,2-dimethylimidazole ligand which have ce:italic>/ce:italic>-Cu-
N2O2 + O2 disposition [41,42]. Comparing the four closest distances
with the analogous ones for the trans-bis(imidazole) bis(salicylato)
copper (II) complex (Cu–N = 1.961 Å; Cu–O = 2.042 Å) [34], the Cu–Fig. 2. View of the molecular structure of [Cu(1,2-MeIm)2(Hsal)2](1). Hydrogen
atoms have been omitted for clarity. Selected bond distances and angles are: Cu–
N1 = 1.979 Å, Cu–O1 = 1.981 Å; Cu–O2 = 2.590 Å; C1–O1 = C1–O2 = 1.265 Å; N1–
Cu–O1 = 92.5 Å; N1A–Cu–O1 = 151.8.N distances are longer and the Cu–O distances are shorter in the
1,2-dimethylimidazole adduct (1). This may be attributed to the
steric hindrance of the methyl substituent groups in 1,2-dimethyl-
imidazole ligand which reﬂects on pulling up imidazole moiety
and enlarging the Cu–N distances (1.979 Å) in this adduct compare
to 1.961 Å for the imidazole adduct. At the same time, oxygen
atoms of the carboxylate groups in the Cu (II) plane will have more
space to come nearer to Cu (II) atom and Cu–O distances become
shorter (1.981 Å) compare with 2.042 Å for the imidazole adduct.
The Cu–O distances of the weakly coordinated carboxylate oxygen
atoms in the axial positions for the imidazole adduct are 2.86 Å
compare with 2.59 Å in 1,2-dimethylimidazole adduct (1). The
N1–Cu–O1 angle is 92.5 (Fig. 2); however, the least square planes
deﬁned by N1–Cu–N1A and O1–Cu–O1A have a dihedral angle of
38.6 as a result of distortion from square symmetry. Since there
is a methyl substituent on the uncoordinated nitrogen atom of
each imidazole ligands, there is no intermolecular hydrogen bond-
ing involving the imidazole ligand and hydroxyl groups of salicy-
late ligands of neighboring molecules. But because the hydroxyl
group lines on the same side of the salicylate ring as the weakly
coordinating carboxylate oxygen atom Fig. 2, intramolecular
hydrogen bondings are formed between these oxygen atoms of
the salicylate ligand. The carboxylate distances C1–O1 and C1–
O2 are the same (about 1.265 Å). The carboxylate function and
the six carbon member ring of the salicylate ligand are twisted
about the C1–C2 bond by only 2.2; thus, the salicylate ion is
essentially planar.3.3. Superoxide dismutase activity
The superoxide dismutase mimetic activities of the complexes
1, 2 and 3 (the copper salicylate imidazole mixture, Cu(Im)n(Hsal)2,
where n = 2, 5, 6), were determined with an indirect method using
the xanthine–xanthine oxidase – INT method [16,20]. The activity
is expressed as IC50 which is the concentration (lM) of the com-
plex or enzyme required to dismutase 50% of the evolved superox-
ide radical anion (O2 ). Fig. 3 shows the percentage inhibition of
INT reduction plotted against the concentration of the complex
Cu(1,2-MeIm)2(Hsal)2(1). Table 2 shows the IC50 values of the com-
plexes under investigation along with the corresponding values of
the copper (II) complexes with salicylate type ligands with or with-
out imidazoles and of the native Cu, Zn–SOD enzyme. The table
contains also, for comparison purposes, the activities of other cop-
per (II) complexes of anti-inﬂammatory drugs such as Cu2(indo)4(-
H2O)2 [where indoH = inodomethacin] which is considered to be
an excellent SOD mimic [12] and is used therapeutically as an oral
anti-inﬂammatory drug in veterinary medicine [2].
All copper (II) salicylate imidazoles complexes we tested in the
present work or previously [20] exhibited signiﬁcant activities
with IC50 values are in the range of 0.17–0.65 lM and their activi-
ties decrease in the order: Cu(N-MeIm)6(Hsal)2(4) > Cu(Im)n(H-
sal)2(3) > Cu(2-MeIm)3(sal)(2) > Cu(1,2-MeIm)2(Hsal)2(1) (the
lower the IC50 value the higher complex activity). It appears that
inclusion of the imidazole nitrogen donor atoms in the plane of
the Cu (II) atom increases the SOD activity. The relatively high
SOD activities of the mixture complexes 3 and 4, with four imidaz-
ole nitrogen atoms in Cu (II) plane, compared to the activities of
complexes 2 and 1 with three and two imidazole nitrogen atom,
respectively, in the Cu (II) plane, may be attributed to the similarity
of coordination site in the former complexes to that for the native
Cu, Zn–SOD enzyme which have four imidazole nitrogen atoms in
its Cu (II) equatorial plane [11].
The dismutation of superoxide anion, by both the native en-
zyme SOD or the copper complexes mimics, is involving redox cy-
cling of Cu (II) ion as following [11]:
Fig. 3. Percentage of inhibition of INT reduction versus copper complex concentra-
tion (lM) for Cu(1,2-MeIm)2(Hsal)2(1).
Table 2
Superoxide dismutase mimetic activity of copper (II) complexes.
Copper complex IC50 (lM) References
[Cu(1,2-MeIm)2(Hsal)2](1) 0.65 This work
[Cu(2-MeIm)3(sal)](2) 0.53 This work













Native Cu, Zn–SOD 0.042 [31]
Where H2sal = salicylic acid; MeIm = methylimidazole; Im =
imidazole; BZDH = benzimidazol; phen = 1,10-phenanthroline;
en = ethylenediamine; Indo = Indomethacin DMF = dimethyl-
formamide; tolf = tolfenamic acid; dic = diclofenac acid; 3,5-
DTBS = 3,5-ditertiarybutyl salicylate; Eth = ethanol.
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CuðIÞ þ O2 þ 2H2 ! CuðIIÞ þH2O2
Hydrogen peroxide formed in this reaction is destroyed in vivo by
the enzyme catalase. The electron transfer between Cu (II) and O2
occurs through direct binding, and the axial site of the copper (II)
complexes is most likely the coordination site of O2 to Cu (II) ion.
Thus for the copper complex to act as good mimics for superoxide
dismutase the following requirements are proposed and may in-
clude: (1) the O2 must gain direct access to the metal ion. A limited
steric hindrance to the approach of the superoxide anion to Cu (II)
coordination site and a fast exchange of molecules axially coordi-
nated to the center are considered essential requirements for suc-
cessful binding of superoxide anion [20,23], (2) a distortion with
ﬂexibility of the copper (II) coordination polyhedron to facilitate
the interaction of the O2 , followed by the rapid electron transfer
reaction which results in reduction to Cu (I) species. The distorted
geometry of the mimic complex may favor the geometrical change
which is essential for the catalysis as the geometry of Cu (II) in
SOD-enzyme changes from distorted square pyramidal to distorted
tetrahedral Cu (I) during catalysis [11], (3) Cu (II) complexes with
coordination sites belonging to nitrogen hetero-aromatic rings such
as imidazoles, pyridines and pyrazoles and ligands with favorable
response of their p-electrons in stabilizing the Cu (II)–O2 interac-tion, are important for high SOD activity [15,23,29,30], and (4) Cu
(II) complexes which have groups capable of forming hydrogen
bonds with the O2 anion or have groups which carry positive
charge are also important for the complex to exhibit good SOD mi-
metic activity. These groups may assist the induction of the O2 to
copper ion and stabilizes its interaction which will result in SOD
activity enhancement as does the Arg 141 residue near the copper
site in the native Cu, Zn–SOD [28,33,45].
The relatively high SOD activity of the complexes under inves-
tigation may be explained in terms of their tetragonally distorted
or square pyramidal distorted geometries around Cu (II) ion and
to limited steric hindrance to the approach of superoxide anion
to coordination site. In these complexes which contain the Cu-
N2O2 + O2 (complex 1), CuN3O + O (complex 2), CuN4 + N2,
CuN4 + N and CuN2O2 + O2 (for the mixture complex 3) or
CuN4 + N2 (complex 4) chromophores, the axial atoms are the
weakly coordinated oxygen atoms from salicylate ions or the imid-
azole nitrogen atoms, which are readily dissociated to provide sites
on Cu (II) for O2 bonding. The dissociation would also facilitate any
necessary geometrical changes induced by O2 bonding during
catalysis as in the native SOD [11]. The presence of salicylate hy-
droxyl group (in complexes 1 and 3) and the free N–H group in
imidazole (complex 3) and 2-methylimidazole (complex 2) which
are capable of forming hydrogen bonds with the O2 anion that
may assist its induction and stabilize its coordination to copper
ion, which will result in SOD activity enhancement for these com-
plexes [28,33,45].
The SOD-like activities which are measured by IC50 values of the
complexes under investigations are comparablewith those IC50 val-
ues reported for the most active SOD mimics [12,15,29–32,45–48].
The IC50 for complex 1 is comparable with that reported for the
trans-bis (benzimidazole)2 bis (salicylato) copper (II) complex
(Table 2) [15]. The IC50 values for complexes 2–4 were of the same
order or better than those obtained for copper complexes showing
pharmacological properties associated with the dismutation of O2
radical, such as those for copper complexes of non-steroidal anti-
inﬂammatory drugs, showing enhanced anti-inﬂammatory effects
[2,5,12,15,16].4. Conclusions
The results obtained from the present study and from our pre-
vious studies [20,34] demonstrated the ability of copper to form di-
verse geometries with the same or similar ligands. Mononuclear
complexes with two, three, ﬁve and six coordinated imidazole or
its methyl derivatives and salicylate ion have been formed from
the interaction of the imidazole ligands with the copper (II) aspiri-
nate dimer, where aspirinate ligand was hydrolyzed during the
reaction to salicylate mono-anion or di-anion. While the interac-
tion of 1,2-dimethylimidazole and 2-methylimidazole with
binuclear copper (II) aspirinate produced the ce:italic>/ce:italic>-
bis (1,2-dimethylimidazole) bis (salicylato) copper (II) adduct (1)
and the tris (2-methylimidazole) (salicylato) copper (II) adduct
(2) respectively, the imidazole and N-methylimidazole interactions
produced a mixture of trans-bis, pentakis-, and hexakis (imidazole)
adducts (3) [34], and hexakis (N-methylimidazole) adduct (4) [20]
as we reported previously.
The complexes (1–4) showed signiﬁcant SOD mimetic activities
with IC50 values are in the range of 0.17–0.65 lM. Although these
IC50 values are still larger than the value reported for native Cu, Zn–
SOD (0.04 M) but are comparable with the IC50 values reported for
the best copper complex mimics [12,15,29–32,45–48]. These com-
plexes are considered potent SOD mimics considering their very
low molecular weights when compared to that of the native Cu,
Zn–SOD enzyme. Further, the complexes are easily formed with
A.L. Abuhijleh / Journal of Molecular Structure 980 (2010) 201–207 207biologically active salicylate and imidazole ligands, and they are
promising antioxidant agents for preventing pathologies in which
free superoxide anion is implicated.References
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